patienc requir
sale remain focu
medium- long-term opportun look strong
remain signific focu revenu ramp embed guidanc
tilt back-half weight follow earn quarterli
revenu modestli expect growth beat
forecast clear focu quarter expect revenu ramp
throughout guid street growth
expect major acceler year-end achiev full-year guidanc
help matter hand novaseq placement slip
manag note placement weight toward although
order track full-year placement forecast remain unchang
revenu ramp driven start-up time sever signific
popul sequenc initi headlin nih genom us
initi major opportun popul sequenc also pursu
uk franc singapor dubai other ultim recommend patienc
view driver ramp question said
acknowledg setup could continu weigh sentiment near term
beyond underli growth clinic appear strong durabl
view import growth driver industri
provid new disclosur exposur clinic repres
sequenc consum grew given grow applic
demand across oncolog liquid biopsi nipt rare diseas view clinic
durabl growth driver time pacbio reiter expect
acquisit close mid-year final modestli rais ep
guidanc account deconsolid helix specif
forecast ep midpoint due sole divest
helix-rel dilut overal continu see substanti underli
momentum around adopt across clinic research set
believ uniqu posit address given reput scale
valu proposit reiter overview rate
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
medium- long-term opportun look strong
remain signific focu revenu ramp embed guidanc
tilt back-half weight follow earn quarterli revenu
modestli expect growth beat forecast clear
focu quarter expect revenu ramp throughout illumina
guid street growth expect major acceler
year-end achiev full-year guidanc help matter hand
novaseq placement slip manag note placement
weight toward although order track full-year placement
forecast remain unchang revenu ramp driven start-up time
sever signific popul sequenc initi headlin nih
genom us initi major opportun popul sequenc also
pursu uk franc singapor dubai other ultim recommend
patienc view driver ramp question
said acknowledg setup could continu weigh sentiment near
beyond underli growth clinic appear strong durabl
view import growth driver industri provid new
disclosur exposur clinic repres sequenc
consum grew given grow applic demand across
oncolog liquid biopsi nipt rare diseas view clinic durabl growth
driver time pacbio reiter expect acquisit close
mid-year final modestli rais ep guidanc account
deconsolid helix specif forecast ep
midpoint due sole divest helix-rel dilut overal
continu see substanti underli momentum around adopt across
clinic research set believ uniqu posit
address given reput scale valu proposit reiter overview
maintain revenu guidanc although number
move part compani expect growth y/i impli revenu
billion embed revenu guidanc fx headwind embed
guidanc mid-teen sequenc revenu sequenc consum
growth strength sequenc expect off-set weak dtc test loss
helix revenu embed guidanc mid-teen growth said
manag take cautiou view consum genet test expect
array revenu roughli flat y/i expect growth impli
revenu repres full-year total gross margin expect flat
slightli oper expens anticip improv tax rate
expect
follow helix deconsolid ep expect rang
midpoint previou guidanc due sole remov
helix dilut helix dilut dilut embed
april result inclus remain aforement dilut
remaind previous assum helix would dilut
keep mind believ pacbio transact dilut base
mid-year close dilut yet embed estim
improv driven growth
revenu expect grow sequenc revenu expect
sequenc system sequenc
consum array revenu expect declin mid-teen percentag basi
lower servic revenu gross margin anticip sequenti due
unfavor product mix non-recurring revenu sequenc servic oper
expens expect increas sequenti revenu final expect
incom declin sequenti
initi guidanc modestli lower initi
expect note good track record recent year deliv
upsid target look back beaten initi revenu
forecast year ep forecast year averag revenu upsid around
translat ep upsid versu initi guidanc addit year
revenu outperform initi guidanc averag beat revenu
ep
guidanc growth gross op base per sharenon-gaap interest extinguish debtleg contingenciescost-method investmentsconting compensationheadquart relocationothergaap slightli slightli barclay illumina inc
track record actual result vs initi guidanc
note adj ep current forecast revenu actual provid present
note novaseq order line expect although time
shipment push hand system expect placement
roughli doubl total comment order
hiseq custom begin transit novaseq view
encourag sign convers opportun novaseq compani still believ
novaseq upgrad cycl span multipl year
approxim high throughput custom begun transit
novaseq expect closer hiseq custom transit
novaseq end drive adopt broader rang custom
announc sever chang lower throughput flow cell strategi
novaseq compani decreas price flow cell
respect combin launch prime sp flow cell compani hope
catalyz placement lower throughput hiseq custom illumina
continu confid novaseq expand whole-genom sequenc
market note novaseq custom new high throughput sequenc
sequenc whole
model estim place novaseq placement
averag consum pull-through follow expect
placement assum novaseq
place repres replac least one hiseq compani start see
cannib hiseq custom well given rel advantag novaseq
forecast billion novaseq revenu year launch
compar million nextseq revenu million hiseq revenu
year launch assumpt model place
novaseq per year hiseq hiseq decommiss persist beyond given multi-
year adopt util increas per novaseq end
model million survey averag sinc assum new custom add
lower overal average
barclay research revenu build
pleas see survey
say elast
upgrad ow
remind survey march-april show signific
demand novaseq continu expect major custom transit toward
platform custom spoke broadli expect de-commiss
hiseq hiseq instal base novaseq addit replac least
instrument across board shown novaseq instal base custom
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i servic y/i array y/i y/i y/i consum instrument barclay illumina inc
spoke expect doubl today next year
expect lead signific reduct hiseq instrument
hiseq instrument collect decreas one custom transit
fleet nextseq onto novaseq instrument interestingli speak one
custom alreadi sold two novaseq anoth lab made
strateg pivot focu bioinformat cater custom buy novaseq
proprietari novaseq custom survey show major transit toward novaseq platform
custom survey expect weight averag budget increas
custom expect budget declin next year broad
rang expect growth matur center project growth
rapidli grow sequenc custom project growth one smaller
research custom cite flat budget use novaseq cost save drive offset
amount volum coverag driver sequenc growth almost everi
custom use depth everi custom expect spend least million per
year consum novaseq weight averag million
believ unlik actual attain level overal instal base
averag sinc new custom addit drag overal novaseq averag
model project million novaseq util per instrument end
result self-report back envelop math suggest
decent approxim compar net instrument add decommiss
project novaseq util would suggest custom survey
increas consum spend gb sequenc
estim custom proprietari novaseq survey increas sequenc spend
revenu grew y/i million million expect overal
post better expect result servic revenu geograph
perspect growth broad-bas quarter growth unit state
growth emea growth asia-pacif region growth
china exclud stock order growth china would result
china benefit sequenc consum nipt oncolog applic
well array
utilizationrev mmpull-through per inst per gbinstal base revsgb seq mm instal base revsgb seq mm revsgb yeary/i chang barclay illumina inc
revenu y/i growth
continu believ china long-term structur growth driver
life scienc research sequenc fit natur countri ambit tackl
long-term societ need transit industri economi servic
economi better compet market china repres
revenu dwarf larger economi like unit state
europ said market experienc signific growth
believ market sustain growth
next sever year eclips billion revenu
expect china drive substanti growth number year
revenu increas y/i million total revenu
consum grew quarter note sequenc consum
revenu associ applic consum associ clinic
applic grew consum associ research appli
applic grew nextseq util came high end guid rang
miseq miniseq util fell within guidanc rang
respect importantli novaseq pull-through expect increas
throughout instrument revenu decreas y/i servic
revenu also strong quarter grow y/i
novaseq high throughput sequenc platform custom focus whole-
genom sequenc advantag rel legaci hiseq hiseq product
line instal base around hiseq hiseq instrument
compani address larg market opportun base instrument sale alon
upsid would driven market expans drive higher consum
revenu said placement cannib exist instrument consum
opportun would limit note consum cost per sampl
like go applic mean consum revenu could
actual declin per-box basi view launch make sens
revolutionari product aim drive replac cycl put rest
concern around revenu visibl near term long-term overcapac
concern like remain compani tri expand market beyond
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
four flow cell option prime sp four flow cell
throughout capabl tb hiseq respect
modestli reduc speed-to-result hiseq day day
novaseq price capabl run three flow cell
earn announc cancel novaseq
flow cell custom primarili demand novaseq instrument
hiseq demand hiseq instrument increas compani announc
longer accept hiseq order decommiss hiseq
quarter importantli focus convert exist hiseq custom
novaseq remind hiseq launch per
system januari announc launch hiseq
enhanc leverag capabl hiseq system hiseq
price reagent price per gb similarli hiseq
price provid half output lower reagent costs/fast run time
hiseq util approxim hiseq consum expect
trend downward throughout beyond note hiseq
consum revenu continu steadi declin project transit novaseq
expect signific replac cycl instrument follow
recent launch prime flow cell said compani note number
custom need finish current project upgrad
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
januari announc sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
high end guid rang move forward illumina
expect nextseq pull-through rang
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
miseq miseq util fell within compani guid rang quarter sinc
launch miniseq encourag lower expect level
miseq cannib ultim believ market desktop
instrument minimum estim place though
could make argument market size product price
unit expect annual pull-through
miniseq/iseq launch januari miniseq compani smallest bench-
top sequenc design target sequenc applic smaller lab cost
instrument roughli pull number quarter
rang model current instal base miniseq iseq
instrument earli januari announc iseq launch
expand portfolio breadth lower-throughput end sequenc
market compani describ iseq inexpens fast easi use sequenc
iseq target address market potenti custom rang
current owner new-to- custom iseq gener million
read greater per run run-tim rang hour price
per sampl rang addit sequenc cost less
instal custom less one hour shipment iseq
began end
array revenu decreas y/i quarter million softer result
driven primarili consum y/i servic revenu increas
quarter addit compani anticip array revenu
roughli flat y/i remind provid in-hous test servic dtc test
compani notabl ancestrydna compani also supplier dtc compani
run volum in-hous partner laboratori
gener revenu consum consum
revenu grew quarter driven sequenc consum look back
increas instal base instrument market consum pull
follow servic revenu revenu grew y/i growth servic
y/i microarray servic y/i
mix revenu instrument vs recur
gross margin improv y/i driven product mix non-recur sequenc
revenu compani non-gaap gross margin y/i
gross margin expect flat slightli keep mind better margin
consum revenu grew y/i revenu ebitda margin
y/i
 ex-comp increas y/i revenu sg ex-comp
increas y/i revenu put togeth total oper expens
 sg stock-bas comp increas y/i revenu
non-gaap sg revenu
non-gaap ep increas y/i top line perform y/i
lower tax rate off-set margin declin compani tax rate declin
ep came estim addit
ep impact dilut helix quarter independ tax benefit
marginadj revenu dsg barclay illumina inc
quarterli non-gaap ep y/i growth
estestestestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base opex ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control interest net adj net growth growth net net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
